Shuffle Most Popular Featured

Press Release

Genentech Announces New STEM Education Initiative to Support South San Francisco Schools


Today's STEM professionals can help inspire the leaders of tomorrow.

Renewing Our Commitment to Sustainability

We reached our 2014 sustainability goals, but we're not stopping there. Learn more about what we're working on for 2020!

From Our Labs: Cell Culture Shock

There’s a deeply unsettling problem in the world of cell cultures used for scientific research. We’re tackling it head-on with an ambitious new solution.

FDA Approval

On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME).

Shutting Down Pain

Many pain medicines were discovered either by accident or by exploring traditional remedies; we're trying to understand the biology of pain using target-based drug discovery.

From Our Labs

Genentech scientists have found that a protein called DLK may play a role in many types of neurodegeneration, with implications for diseases like Alzheimer’s and ALS.

FDA Approval

On November 14, 2014, a Genentech medicine received FDA approval for use in a specific type of platinum-resistant ovarian cancer.

2014 ACR Annual Meeting

Presentations, Posters, and Papers galore. Check out our ACR 2014 newsroom to learn more about our commitment to rheumatology.

2014 AAO Annual Meeting

Genentech will present important new ophthalmic data at the 118th Annual Meeting of the American Academy of Ophthalmology (AAO) from October 18-21 in Chicago.

FDA Approval

On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF).

Genentech Agrees to Acquire Seragon to Strengthen Breast Cancer Pipeline

Read about Genentech’s planned acquisition of Seragon.

New Insights on Breast Cancer Research

With the recent acquisition of Seragon, Genentech is excited to add a new class of investigational medicines known as SERDs to our pipeline.

Sunshine Act: Increasing Transparency

Genentech fully supports efforts to increase transparency around the partnership between the industry and healthcare professionals.

FDA Approval

Medicine for people with chronic idiopathic urticaria (CIU), a form of chronic hives.